This is a working overview of thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Inhalation therapy is carried out in Gasteiner-Heilstollen, Austria; Świeradów-Zdrój, Czerniawa-Zdrój, Kowary, Lądek-Zdrój, Poland; Harghita Băi, Romania; and Boulder, Montana. In the US and Europe, there are several "radon spas", where people sit for minutes or hours in a high-radon atmosphere, such as at Bad Schmiedeberg, Germany.
== History == The concept of residence time originated in models of chemical reactors. The first such model was an axial dispersion model by Irving Langmuir in 1908. This received little attention for 45 years; other models were developed such as the plug flow reactor model and the continuous stirred-tank reactor, and the concept of a washout function (representing the response to a sudden change in the input) was introduced. Then, in 1953, Peter Danckwerts resurrected the axial dispersion model and formulated the modern concept of residence time.
The statement noted: "We cannot celebrate the birthday of a state founded on terrorism, massacres and the dispossession of another people from their land.", "We will celebrate when Arab and Jew live as equals in a peaceful Middle East" Friedrich Pollock (22 May 1894 – 16 December 1970) was a German academic, author, social scientist, philosopher and colleague of Max Horkheimer and Theodor W. Adorno. He was one of the founders of the Institute for Social Research in Frankfurt am Main, and a member of the Frankfurt School of neo-Marxist theory; lived and wrote in London during the Nazi expulsion period, later exiled to Paris and New York. Michael Polanyi (Hungarian: Polányi Mihály; 11 March 1891 – 22 February 1976) was a Hungarian-British polymath and author, who made important theoretical contributions to physical chemistry, economics, and philosophy. Peter Pomerantsev (Russian: Питер Померанцев; born Pyotr Igorevich Pomerantsev, Пётр Игоревич Померанцев; born 1977); Soviet-born journalist, author and TV producer; Senior Fellow at the Institute of Global Affairs at London School of Economics; associate editor at Coda Media; has written two books about Russian disinformation and propaganda—Nothing Is True and Everything Is Possible and This Is Not Propaganda and a third, How to Win an Information War: The Propagandist Who Outwitted Hitler, on Sefton Delmer, British propagandist during World War II.
== Development == Dermal macrophages are either from embryonic progenitors or circulating progenitors. Numerous dermal macrophages are present in the skin at birth due to the infiltration of yolk-sac derived macrophages and haematopoietic stem cell (HSC)-derived monocytes. The prenatal population of dermal macrophages is gradually replaced by the recruitment and differentiation of circulating progenitors in adulthood. Prenatal dermal macrophages are not to be confused with Langerhans cells as they uniquely express CD14 and FXIIIa and lack CD1a.
=== Refrigeration === Around 1938, following a request by Numero, Jones began designing the Thermo Control Model A automatic truck refrigeration unit. Jones designed the portable air-cooling unit for trucks carrying perishable food to prevent spoilage. The Model A refrigeration equipment was attached to undercarriages of trucks. Chilled air was transported to the inside of the trailer via refrigerant tubing. Because Model A was too heavy, Jones later developed the Model B, which was smaller and lighter, but not durable. In 1941, Jones completed development of the Model C, which was mounted to the front of the truck, was compact, light, and withstood road travel vibrations. In 1939, Jones filed for a patent for the Model A and received a patent for it on July 12, 1949. Numero sold his movie sound equipment business to RCA and formed a new company in partnership with Jones, the U.S. Thermo Control Company (later the Thermo King Corporation) which became a $3 million business by 1949. Portable cooling units designed by Jones were especially important during World War II, preserving blood, medicine, and food for use at army hospitals and on open battlefields. Model C units were initially manufactured for military use, but following the war the units became available for commercial use as well.
Sources: en.wikipedia.org
=== Drug discovery problems === In September 2005, Dr. Reddy's spun off its drug discovery and research wing into a separate company called Perlecan Pharma Private Limited. At the time, this was hailed as an innovative move, but in 2008, the company had to be wound down due to funding constraints. Dr. Reddy's was the first Indian pharma company to attempt such an effort to de-couple risk of drug discovery from the parent company by creating a separate company with an external source of funding. Perlecan Pharma was partially funded by ICICI Venture Capital and Citigroup Venture International, both of which held a 43% stake in Perlecan for an estimated $22.5 million. However, the company was forced to buy back the Perlecan shares from ICICI and Citigroup due to doubts regarding the commercial viability of the drug candidates that were in Perlecan's pipeline. At that point, Perlecan became a wholly owned subsidiary. In the board meeting of 23 October 2008, the company chose to amalgamate/absorb Perlecan, thereby making it an in-house research facility, as it was before 2005. In 2009, the company did a U-turn and has handed over discovery research and related intellectual property to its Bangalore-based subsidiary, with the possibility of spinning it off as a different entity altogether. "The company may be hoping to find a strategic partner in the future to share the risks and research funding."
=== Outer membrane and surface antigens === The of T. pallidum has several features that have made it historically difficult to research. These include details such as its fragility. The treponemal outer membrane (OM) proteins are key factors for the bacterium's pathogenesis, persistence, and immune evasion strategies. Treponema's reputation as a "stealth pathogen" is primarily due to this unique (OM) structure, which serves to evade immune detection. The outer membrane of Treponema pallidum contains a strikingly low concentration of transmembrane proteins, approximately 100-fold lower than other gram-negative bacteria or other spirochetes. This protects the cells from antibodies attacking it, hence they exhibit a "puzzling lack of antigenicity". The genome also revealed a bundle of 12 proteins and some putative hemolysins are potential virulence factors of T. pallidum. One protein, TprK, appears to constantly mutate to avoid immune response from its host.
== Matrix-assisted laser desorption/ionization == MALDI is an ionization technique where laser energy is absorbed by a matrix to create ions from large molecules without fragmentation. The matrix, typically in excess, is mixed with the analyte molecule and deposited on a target. A table of matrix compounds, their structures, laser wavelengths typically used, and typical application is shown below.
Topical hydrocortisone is formulated as liquid, solution, lotion, cream, gel, ointment, foam, and spray. The strength of topical hydrocortisone products ranges from 0.1% to 2.5%, which means there could be 1 mg to 25 mg hydrocortisone in 1g of the products. Some formulations for topical hydrocortisone include hydrocortisone 0.5% cream or ointment, hydrocortisone 1% cream or ointment, and hydrocortisone 2.5% cream or ointment. Regarding the method of applying the medications, please refer to the package insert or consult a pharmacist. Some less common forms of topical hydrocortisone are also available in the market. For example, hydrocortisone butyrate is a relatively potent topical hydrocortisone cream that can only be purchased when you have a valid prescription. Besides, some forms of topical hydrocortisone are mixed with antimicrobial drugs to treat bacterial or fungal problems of the skin.
Sources: en.wikipedia.org
==== Plants ==== The reduction of silver ions into silver nanoparticles has also been achieved using geranium leaves. It has been found that adding geranium leaf extract to silver nitrate solutions causes their silver ions to be quickly reduced and that the nanoparticles produced are particularly stable. The silver nanoparticles produced in solution had a size range between 16 and 40 nm. In another study different plant leaf extracts were used to reduce silver ions. It was found that out of Camellia sinensis (green tea), pine, persimmon, ginko, magnolia, and platanus that the magnolia leaf extract was the best at creating silver nanoparticles. This method created particles with a disperse size range of 15 to 500 nm, but it was also found that the particle size could be controlled by varying the reaction temperature. The speed at which the ions were reduced by the magnolia leaf extract was comparable to those of using chemicals to reduce. The use of plants, microbes, and fungi in the production of silver nanoparticles is leading the way to more environmentally sound production of silver nanoparticles. A green method is available for synthesizing silver nanoparticles using Amaranthus gangeticus Linn leaf extract.
About 95 minutes after launch, the satellite flew over its launch site, and its radio signals were picked up by the engineers and military personnel at Tyura-Tam: that's when Korolev and his team celebrated the first successful artificial satellite placed into Earth-orbit. The next satellite sent by the Soviets after Sputnik 1 was Sputnik 2, launched on November 3, 1957, just a month later. This would put the first animal into orbit.
As of 2025, Pakistan's nominal GDP stood at US$407.79 billion, while GDP (PPP) was US$1.8 trillion in 2026. The nominal per capita GDP was US$1,700, and the GDP (PPP)/capita amounted to US$6,950 (international dollars). Around 44.7% of the population live below the international poverty line of US$4.20 a day, 16.5% live in extreme poverty on less than US$3 a day, 8% of the total labour force is unemployed, and CPI inflation in 2025 was 4.5%. Pakistan ranks near the bottom globally on the Global Gender Gap Index's economic participation and opportunity sub-index for women, reflecting very low female labour force participation and limited representation of women in senior economic roles. Pakistan's middle class is estimated to be around 40–50 million people, representing 15–20 per cent of the population. Among South Asian countries, Pakistan's GDP growth rate of 2.5% in 2024 was the second lowest after Afghanistan. Pakistan has strong potential to produce diverse food commodities due to its vast natural resource base across varied ecological and climatic zones. It has the world's 7th-largest labour force, and its diaspora of around 10 million, sent US$38.3 billion in remittances in fiscal year 2024–25, as reported by the Special Investment Facilitation Council. Pakistan's share of global exports averaged 0.14% between 1990 and 2023 and was 0.12% in 2023.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.